主页 > 生命科学 >
【medical-news】多柔比星加酮康唑作为二线治疗方
In the experience of Dr. Aristotelis Bamias of the University of Athens Medical School and colleagues, it is a convenient, well-tolerated treatment in this patient population, with efficacy comparable with that of other reported therapies.
For patients with hormone-refractory prostate cancer who fail first-line treatment with docetaxel, the prognosis is poor and no second-line treatment has been established, the investigators note. Doxorubicin has demonstrated activity against prostate cancer, as has the antifungal agent ketoconazole.
In the June issue of Urology, Dr. Bamias and colleagues report outcomes of 34 patients with androgen-independent prostate cancer who received doxorubicin, 30 mg/m every 2 weeks, and ketoconazole daily (400 mg orally every 8 hours). All patients had been treated with docetaxel and had disease progression within 6 months after completion of first-line treatment.
Of 32 evaluable patients, 13 (43.7%) had a prostate-specific antigen response, and 4 of 14 patients (28%) with measurable disease had a response to therapy.
The median time to progression was 3.9 months and the median overall survival was 13 months, with 8 patients still alive at 20 months. "This is comparable to that reported in a few previous studies," the authors note.
Toxicity was mild, with only 4 cases of nonhematologic grade 3 or 4 toxicity noted. The most common toxicity was grade 1 nail changes (33 of 34 patients).
Biweekly doxorubicin plus ketoconazole, Dr. Bamias and colleagues conclude, is an effective, well-tolerated and convenient second-line treatment for hormone-refractory prostate cancer.
"Nevertheless, the prognosis of these patients remains poor, and research should continue on developing more efficient therapies against this disease," they write.
Urology 2008;71:1181-1185. [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-01 14:39
医学,生命科学网